Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Dec 09, 2024
- Pharmaceuticals
- R&D
Roche Announces New Five-Year Data of Polivy for Previously Untreated Diffuse Large B-cell Lymphoma
TOKYO, December 9, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release on December 8, regarding five-year data from POLARIX study of Polivy® (generic name: polatuzumab vedotin) for previously untreated diffuse large B-cell lymphoma (DLBCL). The data was presented at the 66th American Society of Hematology (ASH) Annual Meeting.
Please refer to the link below for details of the press release:
Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
https://www.roche.com/media/releases/med-cor-2024-12-08
Trademarks used or mentioned in this release are protected by laws.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp